RecruitingPhase 1NCT06419686

The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals

The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals


Sponsor

University Hospital, Gentofte, Copenhagen

Enrollment

10 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The study is a randomised, double-blinded, placebo-controlled, crossover study enrolling 10 healthy male participants. Each participant will undergo four separate study days in randomised order. Each study day encompasses a continous 90-minute i.v. infusion with either placebo, glucose-dependent insulinotropic polypeptide (GIP), alanine or GIP + alanine. The primary objective of the study is to find out whether intravenous administration of the naturally occuring gut hormone GIP and the amino acid alanine, separately and combined, results in additive or synergistic glucagonotropic effects during euglycaemic conditions in healthy participants. Secondary objectives are to disclose the effect of the abovementioned interventions on insulin secretion and circulating levels of total and individual amino acids.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 70 Years

Inclusion Criteria4

  • Caucasian ethnicity
  • Body mass index (BMI) 20-27 kg/m\^2
  • Glycated haemoglobin (HbA1c) ≤ 42 mmol/mol
  • Informed and written consent

Exclusion Criteria6

  • Late microvascular complications except mild nonproliferative retinopathy
  • Liver disease (alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) > 2 times normal values) or history of hepatobiliary disorder
  • Treatment with any glucose-lowering drugs
  • Active or recent (within 5 years) malignant disease
  • Active tobacco smoking/use
  • Any condition considered incompatible with participation by the investigators.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPlacebo (saline)

Intravenous saline during experimental days.

DRUGGIP

Intravenous GIP administration during experimental days.

DRUGAlanine

Intravenous alanine administration during experimental days.

DRUGGIP + alanine

Intravenous administration of GIP and alanine during experimental days.


Locations(1)

Center for Clinical Metabolic Research, Gentofte Hospital

Hellerup, Capital Region, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06419686